Á¦16ȸ °©»ó¼±¿¬¼öȸ : 2019-06-15±³À°ÀÏÀÚ : 2019-06-15
±³À°Àå¼Ò : ÇѾç´ëÇб³ HIT 6Ãþ ´ë°´ç
±³À°ÁÖÁ¦ :
Á¦16ȸ °©»ó¼±¿¬¼öȸÁÖÃÖ±â°ü : ´ëÇѵΰæºÎ¿Ü°úÇÐȸ
´ã´çÀÚ : À̽¾Æ
¿¬¶ôó : 070-4108-7957
À̸ÞÀÏ :
ksthns1990@gmail.com ±³À°Á¾·ù : À̺ñÀÎÈÄ°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Àü¹®ÀÇ »çÀüµî·Ï 4¸¸¿ø ÇöÀåµî·Ï 5¸¸¿ø Àü°øÀÇ »çÀüµî·Ï 3¸¸¿ø ÇöÀåµî·Ï 4¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 06-15 ´ë°´ç 08:00~08:20 Registration ()
±âŸ 06-15 ´ë°´ç 08:20~08:30 Opening Remark Å°æ(ÇѾçÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 08:30~08:45 Thyroid Cancer Epidemiology and Screening ¼Ûâ¸é(ÇѾçÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 08:45~09:00 The New Bethesda System 2017 - What are the Changes? ½Å¼öÁø(ÇѾçÀÇ´ë º´¸®°ú)
±³À°½Ã°£ 06-15 ´ë°´ç 09:00~09:15 Molecular Analysis of Thyroid Nodule ÁÖ¿µÈÆ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 09:15~09:30 Ultrasonographic Risk Stratification of Thyroid Nodule ±èÁ¤±Ô(´ë±¸°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 09:30~09:45 AJCC staging of thyroid cancer: What are the changes? ±èÇѼö(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 09:45~10:00 International Guidelines: Primary thyroid surgery for DTC À̱¹Çà(¿øÀÚ·ÂÀÇÇпø)
±³À°½Ã°£ 06-15 ´ë°´ç 10:00~10:15 Active surveillance of PTC: Where are we standing? ¿ìÁ¤¼ö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 10:15~10:30 Transoral Vestibular Approach Thyroid and Parathyroid Surgery: The Promise and Value of Leaving No Trace Ralph P. Tufano(USA)
ÈÞ½Ä 06-15 ´ë°´ç 10:30~10:45 coffee break ()
±³À°½Ã°£ 06-15 ´ë°´ç 10:45~11:15 Management of Neck in PTC: From Controversy to Consensus Sefik Hosal(Turkey)
±³À°½Ã°£ 06-15 ´ë°´ç 11:15~11:30 IONM in Thyroid Surgury: Basics and New Guidelines Áö¿ë¹è(ÇѾçÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 11:30~11:40 Non-endotracheal tube based IONM with the needle or skin adhesive electrode ÀÌ°´ë(°í½ÅÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 11:40~11:55 Parathyroid Identification and Preservation with Auto-fluorescence ±è¼º¿ø(°í½ÅÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 11:55~12:10 Management of Invasion and Injury of the RLN: Improvement of voice À̽¿ø(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 12:10~12:25 Management of Postthyroidetomy Hypocalcemia and Hypoparathyroidism ±¸º»¼®(Ãæ³²ÀÇ´ë)
½Ä»ç 06-15 ´ë°´ç 12:25~13:25 lunch ()
±³À°½Ã°£ 06-15 ´ë°´ç 13:25~13:55 Forecasting the Next Edition of the ATA Guidelines for the Management of Thyroid Nodules and Differentiated Thyroid Cancer Ralph P. Tufano(USA)
±³À°½Ã°£ 06-15 ´ë°´ç 13:55~14:10 Surgical Management of Areodigestive Tract Invasion ±èöȣ(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 14:10~14:30 RAI Ablation: Who, Why, When and How? ±èÁö¿µ(ÇѾçÀÇ´ë ÇÙÀÇÇаú)
±³À°½Ã°£ 06-15 ´ë°´ç 14:30~14:45 Long-term Follow-up of DTC patients: Which tests? How often? How long? ÀÓâÈÆ(Á¦ÀϺ´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 06-15 ´ë°´ç 14:45~15:00 Management of Loco-regional Recurrent Cancer ¹é½Â±¹(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 15:00~15:15 Systemic Therapy for Refractory or Metastatic Thyroid Cancer °íÀ±¿ì(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 06-15 ´ë°´ç 15:15~15:30 coffee break ()
±³À°½Ã°£ 06-15 ´ë°´ç 15:30~15:45 The role of multidisciplinary team in the management of thyroid cancer Sefik Hosal(Turkey)
±³À°½Ã°£ 06-15 ´ë°´ç 15:45~16:00 Management of Follicular Neoplasm and Cancer À̼¼¿µ(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 16:00~16:15 Diagnosis and RET mutation of MTC ¹ÚÀϼ®(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 16:15~16:30 Surgical Management of MTC Á¤¿µÈ£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 16:30~16:45 Management of Anaplastic carcinoma À̺´ÁÖ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 06-15 ´ë°´ç 16:45~17:30 Case presentor ÀÌÇü½Å(°í½ÅÀÇ´ë)